Article
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
The New England journal of medicine - 27 Aug 2020
Wirth Lori J, Sherman Eric, Robinson Bruce, Solomon Benjamin, Kang Hyunseok, Lorch Jochen, Worden Francis, Brose Marcia, Patel Jyoti, Leboulleux Sophie, Godbert Yann, Barlesi Fabrice, Morris John C, Owonikoko Taofeek K, Tan Daniel S W, Gautschi Oliver, Weiss Jared, de la Fouchardière Christelle, Burkard Mark E, Laskin Janessa, Taylor Matthew H, Kroiss Matthias, Medioni Jacques, Goldman Jonathan W, Bauer Todd M, Levy Benjamin, Zhu Viola W, Lakhani Nehal, Moreno Victor, Ebata Kevin, Nguyen Michele, Heirich Dana, Zhu Edward Y, Huang Xin, Yang Luxi, Kherani Jennifer, Rothenberg S Michael, Drilon Alexander, Subbiah Vivek, Shah Manisha H, Cabanillas Maria E
Abstract excerpt
BACKGROUND: RET mutations occur in 70% of medullary thyroid cancers, and RET fusions occur rarely in other thyroid cancers. In patients with RET-altered thyroid cancers, the efficacy and safety of selective RET inhibition are unknown. METHODS: We enrolled patients with RET-mutant medullary thyroid cancer with or without previous vandetanib or cabozantinib treatment, as well as those with previously treated RET...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.